Retrophin Inc (RTRX) Insider William E. Rote Sells 1,625 Shares

Retrophin Inc (NASDAQ:RTRX) insider William E. Rote sold 1,625 shares of the business’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $17.77, for a total value of $28,876.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

William E. Rote also recently made the following trade(s):

  • On Tuesday, February 19th, William E. Rote sold 1,250 shares of Retrophin stock. The shares were sold at an average price of $21.52, for a total transaction of $26,900.00.
  • On Friday, February 15th, William E. Rote sold 1,250 shares of Retrophin stock. The shares were sold at an average price of $21.44, for a total transaction of $26,800.00.
  • On Tuesday, February 19th, William E. Rote sold 2,500 shares of Retrophin stock. The shares were sold at an average price of $21.48, for a total transaction of $53,700.00.

Shares of Retrophin stock traded up $0.44 on Friday, hitting $19.01. 412,622 shares of the company traded hands, compared to its average volume of 373,252. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.52 and a current ratio of 4.57. Retrophin Inc has a 52 week low of $17.53 and a 52 week high of $33.00. The company has a market capitalization of $769.48 million, a PE ratio of -7.48 and a beta of 0.91.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.99) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.41). Retrophin had a negative net margin of 75.75% and a negative return on equity of 41.38%. The company had revenue of $39.57 million for the quarter, compared to the consensus estimate of $41.40 million. During the same period in the prior year, the firm posted ($0.14) EPS. The business’s revenue was up 3.0% on a year-over-year basis. On average, analysts forecast that Retrophin Inc will post -3.02 earnings per share for the current year.

Several analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Retrophin from a “hold” rating to a “sell” rating in a research note on Tuesday. Barclays assumed coverage on shares of Retrophin in a research note on Monday, April 22nd. They set an “overweight” rating and a $36.00 price target for the company. BidaskClub downgraded shares of Retrophin from a “sell” rating to a “strong sell” rating in a research note on Friday, April 19th. William Blair reaffirmed an “outperform” rating on shares of Retrophin in a research note on Wednesday, April 17th. Finally, ValuEngine downgraded shares of Retrophin from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. Retrophin has a consensus rating of “Hold” and a consensus target price of $45.67.

A number of large investors have recently modified their holdings of the stock. BlueMountain Capital Management LLC raised its stake in Retrophin by 204.3% in the first quarter. BlueMountain Capital Management LLC now owns 30,550 shares of the biopharmaceutical company’s stock worth $691,000 after buying an additional 20,511 shares in the last quarter. Opaleye Management Inc. bought a new position in Retrophin in the first quarter worth approximately $4,639,000. Macquarie Group Ltd. raised its stake in Retrophin by 10.3% in the first quarter. Macquarie Group Ltd. now owns 2,499,076 shares of the biopharmaceutical company’s stock worth $56,555,000 after buying an additional 233,152 shares in the last quarter. Geode Capital Management LLC raised its stake in Retrophin by 10.8% in the first quarter. Geode Capital Management LLC now owns 535,438 shares of the biopharmaceutical company’s stock worth $12,116,000 after buying an additional 52,355 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Retrophin by 6.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 292,406 shares of the biopharmaceutical company’s stock worth $6,618,000 after buying an additional 17,807 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Modern Readers and is the sole property of of Modern Readers. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.modernreaders.com/news/2019/05/17/retrophin-inc-rtrx-insider-william-e-rote-sells-1625-shares.html.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

See Also: What is Cost of Capital?

Insider Buying and Selling by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.